Memo Therapeutics

The Pharma Letter M&A round-up – July 2026 - The Pharma Letter

The Pharma Letter M&A round-up – July 2026  The Pharma Letter

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline - GlobeNewswire

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline  GlobeNewswire

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline - The Manila Times

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline  The Manila Times

Ipsen to acquire Memo Therapeutics in deal worth more than €700m - PMLiVE

Ipsen to acquire Memo Therapeutics in deal worth more than €700m  PMLiVE

Ipsen pens $800m Memo for kidney transplant patients - BioXconomy

Ipsen pens $800m Memo for kidney transplant patients  BioXconomy

Ipsen strengthens rare disease pipeline with €700m acquisition of Memo Therapeutics - European Pharmaceutical Review

Ipsen strengthens rare disease pipeline with €700m acquisition of Memo Therapeutics  European Pharmaceutical Review